These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

212 related articles for article (PubMed ID: 23406852)

  • 21. Intestinal CREBH overexpression prevents high-cholesterol diet-induced hypercholesterolemia by reducing
    Kikuchi T; Orihara K; Oikawa F; Han SI; Kuba M; Okuda K; Satoh A; Osaki Y; Takeuchi Y; Aita Y; Matsuzaka T; Iwasaki H; Yatoh S; Sekiya M; Yahagi N; Suzuki H; Sone H; Nakagawa Y; Yamada N; Shimano H
    Mol Metab; 2016 Nov; 5(11):1092-1102. PubMed ID: 27818935
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors: Present perspectives and future horizons.
    Yadav K; Sharma M; Ferdinand KC
    Nutr Metab Cardiovasc Dis; 2016 Oct; 26(10):853-62. PubMed ID: 27352986
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Proprotein convertase subtilisin kexin 9 inhibitors: next generation in lipid-lowering therapy.
    Milionis H; Liamis G; Elisaf M
    Expert Opin Biol Ther; 2015 Feb; 15(2):287-98. PubMed ID: 25491324
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [New antilipemics: prospects].
    Farnier M
    Therapie; 2003; 58(1):97-105. PubMed ID: 12822207
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Peroxisome proliferator-activated receptor agonists, hyperlipidaemia, and atherosclerosis.
    Vosper H; Khoudoli GA; Graham TL; Palmer CN
    Pharmacol Ther; 2002 Jul; 95(1):47-62. PubMed ID: 12163127
    [TBL] [Abstract][Full Text] [Related]  

  • 26. PCSK9 and lipid lowering drugs.
    Guo YL; Zhang W; Li JJ
    Clin Chim Acta; 2014 Nov; 437():66-71. PubMed ID: 25036764
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Effects of K-877, a novel selective PPARα modulator, on small intestine contribute to the amelioration of hyperlipidemia in low-density lipoprotein receptor knockout mice.
    Takei K; Nakagawa Y; Wang Y; Han SI; Satoh A; Sekiya M; Matsuzaka T; Shimano H
    J Pharmacol Sci; 2017 Apr; 133(4):214-222. PubMed ID: 28366492
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Toward an international consensus-Integrating lipoprotein apheresis and new lipid-lowering drugs.
    Stefanutti C; Julius U; Watts GF; Harada-Shiba M; Cossu M; Schettler VJ; De Silvestro G; Soran H; Van Lennep JR; Pisciotta L; Klör HU; Widhalm K; Moriarty PM;
    J Clin Lipidol; 2017; 11(4):858-871.e3. PubMed ID: 28572002
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Low-Density Lipoprotein Receptor-Dependent and Low-Density Lipoprotein Receptor-Independent Mechanisms of Cyclosporin A-Induced Dyslipidemia.
    Kockx M; Glaros E; Leung B; Ng TW; Berbée JF; Deswaerte V; Nawara D; Quinn C; Rye KA; Jessup W; Rensen PC; Meikle PJ; Kritharides L
    Arterioscler Thromb Vasc Biol; 2016 Jul; 36(7):1338-49. PubMed ID: 27150391
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Evaluation of proprotein convertase subtilisin/kexin type 9: focus on potential clinical and therapeutic implications for low-density lipoprotein cholesterol lowering.
    Lose JM; Dorsch MP; Bleske BE
    Pharmacotherapy; 2013 Apr; 33(4):447-60. PubMed ID: 23553812
    [TBL] [Abstract][Full Text] [Related]  

  • 31. New lipid-lowering drugs: an update.
    Wierzbicki AS; Hardman TC; Viljoen A
    Int J Clin Pract; 2012 Mar; 66(3):270-80. PubMed ID: 22340447
    [TBL] [Abstract][Full Text] [Related]  

  • 32. PCSK9 Inhibitors: An Innovative Approach to Treating Hyperlipidemia.
    Sible AM; Nawarskas JJ; Anderson JR
    Cardiol Rev; 2016; 24(3):141-52. PubMed ID: 26886466
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The high-fat high-fructose hamster as an animal model for niacin's biological activities in humans.
    Connolly BA; O'Connell DP; Lamon-Fava S; LeBlanc DF; Kuang YL; Schaefer EJ; Coppage AL; Benedict CR; Kiritsy CP; Bachovchin WW
    Metabolism; 2013 Dec; 62(12):1840-9. PubMed ID: 24035454
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Profile of evolocumab and its potential in the treatment of hyperlipidemia.
    Cicero AF; Colletti A; Borghi C
    Drug Des Devel Ther; 2015; 9():3073-82. PubMed ID: 26109850
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Combination of berberine and evodiamine inhibits intestinal cholesterol absorption in high fat diet induced hyperlipidemic rats.
    Zhou X; Ren F; Wei H; Liu L; Shen T; Xu S; Wei J; Ren J; Ni H
    Lipids Health Dis; 2017 Dec; 16(1):239. PubMed ID: 29228954
    [TBL] [Abstract][Full Text] [Related]  

  • 36. CM3-SII polysaccharide obtained from Cordyceps militaris ameliorates hyperlipidemia in heterozygous LDLR-deficient hamsters by modulating gut microbiota and NPC1L1 and PPARα levels.
    Yu WQ; Wang XL; Ji HH; Miao M; Zhang BH; Li H; Zhang ZY; Ji CF; Guo SD
    Int J Biol Macromol; 2023 Jun; 239():124293. PubMed ID: 37011745
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Beneficial effects of fish liver preparations of sea bass (Lates calcarifer) versus gemfibrozil in high fat diet-induced lipid-intolerant rats.
    Rizvi F; Iftikhar M; George JP
    J Med Food; 2003; 6(2):123-8. PubMed ID: 12935323
    [TBL] [Abstract][Full Text] [Related]  

  • 38. 2017 Taiwan lipid guidelines for high risk patients.
    Li YH; Ueng KC; Jeng JS; Charng MJ; Lin TH; Chien KL; Wang CY; Chao TH; Liu PY; Su CH; Chien SC; Liou CW; Tang SC; Lee CC; Yu TY; Chen JW; Wu CC; Yeh HI;
    J Formos Med Assoc; 2017 Apr; 116(4):217-248. PubMed ID: 28242176
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Study on anti-hyperlipidemia mechanism of high frequency herb pairs by molecular docking method].
    Jiang LD; He YS; Chen X; Tao O; Li GY; Zhang YL
    Zhongguo Zhong Yao Za Zhi; 2015 Jun; 40(12):2413-9. PubMed ID: 26591535
    [TBL] [Abstract][Full Text] [Related]  

  • 40.
    Zhang Y; Liu T; Qu ZJ; Wang X; Song WG; Guo SD
    Cardiovasc Ther; 2024; 2024():8649365. PubMed ID: 38375358
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.